Bristol Repositions Glucovance, Glucophage XR As Metformin Generics Loom
Executive Summary
A money-back guarantee will be part of Bristol-Myers Squibb's repositioning efforts for the metformin line extensions Glucophage XR and Glucovance.
You may also be interested in...
Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs
Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business
Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs
Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business
Bristol BuSpar Share Halved By Generics; DuPont Deal Shows "Flexibility"
Bristol-Myers Squibb's BuSpar (buspirone) market share has been cut by more than half since the launch of generic products at the end of March.